Details for New Drug Application (NDA): 210331
✉ Email this page to a colleague
The generic ingredient in YUTIQ is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
Summary for 210331
Tradename: | YUTIQ |
Applicant: | Alimera Sciences Inc |
Ingredient: | fluocinolone acetonide |
Patents: | 2 |
Pharmacology for NDA: 210331
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 210331
Suppliers and Packaging for NDA: 210331
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331 | NDA | Alimera Sciences, Inc. | 68611-180 | 68611-180-01 | 1 POUCH in 1 CARTON (68611-180-01) / 1 APPLICATOR in 1 POUCH / 1 IMPLANT in 1 APPLICATOR |
YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331 | NDA | EyePoint Pharmaceuticals, Inc | 71879-136 | 71879-136-01 | 1 POUCH in 1 BOX, UNIT-DOSE (71879-136-01) / 1 APPLICATOR in 1 POUCH / 1 IMPLANT in 1 APPLICATOR |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | IMPLANT;INTRAVITREAL | Strength | 0.18MG | ||||
Approval Date: | Oct 12, 2018 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jan 12, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | A METHOD OF INJECTING AN IMPLANT | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Aug 12, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 210331
Complete Access Available with Subscription